ClinicalTrials.gg
CompletedNCT04508426Updated Nov 16, 2020

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

A Phase 1 interventional study of [14C]AR882 in Healthy Volunteers, sponsored by Arthrosi Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-16.

Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single dose of [14C]AR882 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 144 hours following the single dose of AR882 to measure total radioactivity and plasma drug concentrations.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight no less than 50 kg and (BMI) within the range of ≥ 18 and ≤ 33 kg/m2
  • Must have a minimum of 1 bowel movement every 2 days
  • Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs

Exclusion criteria

Exclusion Criteria:

  • Inadequate venous access or unsuitable veins for repeated venipuncture
  • Positive serology to (HIV1 and HIV2) and/or antibodies, and/or
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Mass Balance

    Drug: [14C]AR882

Interventions

06

What researchers measure

Primary outcomes

  1. Total radioactivity (TRA) in urine

    Time frame: Days 1-14

  2. TRA in feces

    Time frame: Days 1-14

  3. TRA concentration equivalents in plasma

    Time frame: Days 1-14

  4. TRA concentration equivalents in whole blood

    Time frame: Days 1-14

  5. Area under the curve (AUC) for plasma [14C]-AR882

    Profile from plasma in terms of AUC following a single dose of \[14C\]-AR882

    Time frame: 7 Days

  6. Time to maximum plasma concentration (Tmax) for [14C]-AR882

    Profile from plasma in terms of Tmax following a single dose of \[14C\]-AR882

    Time frame: 7 Days

  7. Maximum plasma concentration (Cmax) for [14C]-AR882

    Profile from plasma in terms of Cmax following a single dose of \[14C\]-AR882

    Time frame: 7 Days

  8. Apparent terminal half-life (t1/2) for [14C]-AR882

    Profile from plasma in terms of t1/2 following a single dose of \[14C\]-AR882

    Time frame: 7 Days

Secondary outcomes

  1. Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs [14C]-AR882

    Time frame: Days 1-14

07

Study locations

1 site
  • Celerion, Inc.
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Aug 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2020
First posted
Aug 11, 2020
StartActual
Jul 16, 2020
Primary completionActual
Aug 12, 2020
CompletionActual
Aug 12, 2020
Last update
Nov 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04508426
Collaborators
Celerion
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Jul 16, 2020
Primary completion
Aug 12, 2020
Completion
Aug 12, 2020
Last update
Nov 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AR882

Start the discussion